Siegfried Holding AG
SIX:SFZN

Watchlist Manager
Siegfried Holding AG Logo
Siegfried Holding AG
SIX:SFZN
Watchlist
Price: 81 CHF -0.61% Market Closed
Market Cap: CHf3.7B

Siegfried Holding AG
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Siegfried Holding AG
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Siegfried Holding AG
SIX:SFZN
Stock-Based Compensation
CHf7.8m
CAGR 3-Years
-9%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Bachem Holding AG
SIX:BANB
Stock-Based Compensation
CHf3.4m
CAGR 3-Years
65%
CAGR 5-Years
21%
CAGR 10-Years
16%
Lonza Group AG
SIX:LONN
Stock-Based Compensation
CHf57m
CAGR 3-Years
21%
CAGR 5-Years
5%
CAGR 10-Years
13%
Tecan Group AG
SIX:TECN
Stock-Based Compensation
CHf3.1m
CAGR 3-Years
-39%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Stock-Based Compensation
€2m
CAGR 3-Years
21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Siegfried Holding AG
Glance View

Nestled in the picturesque landscapes of Zofingen, Switzerland, Siegfried Holding AG operates as a key player in the global pharmaceutical supply chain, crafting a narrative of innovation and precision. With roots tracing back to 1873, this stalwart company has evolved over the decades, now standing as a leading supplier of active pharmaceutical ingredients (APIs) and finished dosage forms to the pharmaceutical industry. Siegfried's operations are defined by a seamless integration of chemistry and technology, embodying Swiss precision in every facet of its production process. The company's trajectory is marked by strategic expansions and acquisitions, allowing it to amass a presence in both Europe and North America, crafting a network that ensures its reliability and reach. At the heart of Siegfried's success lies its business model, a symbiotic partnership with pharmaceutical companies that rely on its vast expertise to bring their products to market. Siegfried essentially straddles both ends of the pharmaceutical value chain, deriving revenue by providing essential APIs as well as a robust offering of finished drugs. The company excels in tailor-made solutions, offering complex manufacturing processes that meet stringent regulatory demands. This dual capability not only diversifies its revenue streams but also buffers it against the volatile dynamics of the pharmaceutical industry. With a focus on quality and customer-centric innovation, Siegfried continues to carve a niche as a trusted collaborator, underpinning the development of health solutions worldwide.

SFZN Intrinsic Value
79.15 CHF
Overvaluation 2%
Intrinsic Value
Price CHf81

See Also

What is Siegfried Holding AG's Stock-Based Compensation?
Stock-Based Compensation
7.8m CHF

Based on the financial report for Dec 31, 2025, Siegfried Holding AG's Stock-Based Compensation amounts to 7.8m CHF.

What is Siegfried Holding AG's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
-1%

Over the last year, the Stock-Based Compensation growth was 1 521%. The average annual Stock-Based Compensation growth rates for Siegfried Holding AG have been -9% over the past three years , -1% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett